{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '14 Einstein Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 6.3,
 'askSize': 800,
 'averageDailyVolume10Day': 73612,
 'averageVolume': 115358,
 'averageVolume10days': 73612,
 'beta': None,
 'beta3Year': None,
 'bid': 5.11,
 'bidSize': 1200,
 'bookValue': 2.387,
 'category': None,
 'circulatingSupply': None,
 'city': 'Nes Ziona',
 'companyOfficers': [],
 'country': 'Israel',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 5.6972,
 'dayLow': 5.4,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -5.252,
 'enterpriseToRevenue': None,
 'enterpriseValue': 41688596,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '972 2 670 8070',
 'fiftyDayAverage': 5.6140857,
 'fiftyTwoWeekHigh': 44.9,
 'fiftyTwoWeekLow': 3.59,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 7311210,
 'forwardEps': -1.12,
 'forwardPE': -4.919643,
 'fromCurrency': None,
 'fullTimeEmployees': 36,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.42084998,
 'heldPercentInstitutions': 0.12589,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1551830400,
 'lastSplitFactor': '1:8',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/enlivex.com',
 'longBusinessSummary': 'Enlivex Therapeutics Ltd., a clinical stage '
                        'immunotherapy company, engages in developing '
                        'allogeneic drugs for immune system rebalancing. Its '
                        'product candidate is Allocetra, an immunotherapy '
                        'candidate for the prevention of complications post '
                        'bone marrow transplantations; treatment of patients '
                        'that do not respond to steroid treatment upon '
                        'occurrence of graft vs host disease post bone marrow '
                        'transplantations; and prevention of cytokine storms, '
                        'organ damage, and multiple organ failure in sepsis '
                        'patients. The company also intends to develop its '
                        'cell-based therapy to be combined with treatments of '
                        'solid tumors via immune checkpoint rebalancing to '
                        'enhance the efficacy of various anti-cancer '
                        'therapies, including chimeric antigen receptor T-Cell '
                        'therapy and therapies targeting T-Cell receptor '
                        'therapy. Enlivex Therapeutics Ltd. was founded in '
                        '2005 and is headquartered in Nes Ziona, Israel.',
 'longName': 'Enlivex Therapeutics Ltd.',
 'market': 'us_market',
 'marketCap': 73987736,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_84011067',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -7711000,
 'nextFiscalYearEnd': 1640908800,
 'open': 5.46,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '972 2 670 8072',
 'previousClose': 5.55,
 'priceHint': 2,
 'priceToBook': 2.3083367,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 5.6972,
 'regularMarketDayLow': 5.4,
 'regularMarketOpen': 5.46,
 'regularMarketPreviousClose': 5.55,
 'regularMarketPrice': 5.46,
 'regularMarketVolume': 22320,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 13427900,
 'sharesPercentSharesOut': 0.0008,
 'sharesShort': 10822,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 22109,
 'shortName': 'Enlivex Therapeutics Ltd.',
 'shortPercentOfFloat': 0.0011999999,
 'shortRatio': 0.06,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ENLV',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.732,
 'twoHundredDayAverage': 6.1830144,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'b74cb9f5-e16c-38f4-8a35-7f19c807ad7d',
 'volume': 22320,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.enlivex.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '7403618'}